UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049834
Receipt number R000056765
Scientific Title Exploring the utility of enzyme-linked immunospot assays in previous COVID-19 and SARS-CoV-2 vaccinated individuals
Date of disclosure of the study information 2022/12/19
Last modified on 2022/12/19 23:34:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploring the utility of enzyme-linked immunospot assays in previous COVID-19 and SARS-CoV-2 vaccinated individuals

Acronym

Exploring the utility of enzyme-linked immunospot assays in previous COVID-19 and SARS-CoV-2 vaccinated individuals

Scientific Title

Exploring the utility of enzyme-linked immunospot assays in previous COVID-19 and SARS-CoV-2 vaccinated individuals

Scientific Title:Acronym

Exploring the utility of enzyme-linked immunospot assays in previous COVID-19 and SARS-CoV-2 vaccinated individuals

Region

Japan


Condition

Condition

COVID-19

Classification by specialty

Infectious disease

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In this study, we evaluated various participants, twice/once vaccinated and with/without a COVID-19 history, using the ELISPOT assay and ELISA to assess cellular and humoral immunity against COVID-19. Participants were asked to complete a questionnaire survey to determine symptoms during infection for those affected by COVID-19 and adverse reactions after vaccination for those vaccinated. These results provide new insights into the relationship between symptomatic infection and cellular immunity.

Basic objectives2

Others

Basic objectives -Others

Same as Objective 1

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

COVID-19 immunity status measured by ELISA and ELISPOT assay in populations with different COVID-19 infection histories and vaccinated statuses

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

Group 1: five participants who had recovered from COVID-19 and had received only one dose of COVID-19 mRNA vaccine after COVID-19; Group 2: five participants who had recovered from COVID-19 and had received two doses of COVID-19 mRNA vaccine after COVID-19; and Group 3: 20 participants who had received two doses of COVID-19 mRNA vaccine and had no history of COVID-19

Key exclusion criteria

If the applicant does not meet the age criteria or it is difficult to obtain his/her consent

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Kenji
Middle name
Last name Sawaki

Organization

The Jikei University School of Medicine

Division name

Department of Infectious Diseases and Infection Control

Zip code

105-8461

Address

3-25-8, Nishi-shinbashi, Minato-ku, Tokyo

TEL

03-3433-1111

Email

k_sawaki@jikei.ac.jp


Public contact

Name of contact person

1st name Kenji
Middle name
Last name Sawaki

Organization

The Jikei University School of Medicine

Division name

Department of Infectious Diseases and Infection Control

Zip code

105-8461

Address

3-25-8, Nishi-shinbashi, Minato-ku, Tokyo

TEL

03-3433-1111

Homepage URL


Email

k_sawaki@jikei.ac.jp


Sponsor or person

Institute

The Jikei University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Jikei University School of Medicine

Address

3-25-8, Nishi-shinbashi, Minato-ku, Tokyo

Tel

03-3433-1111

Email

crb@jikei.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 12 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

30

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2021 Year 12 Month 06 Day

Date of IRB

2021 Year 12 Month 13 Day

Anticipated trial start date

2021 Year 12 Month 14 Day

Last follow-up date

2021 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Blood test: the T-SPOT Discovery SARS-CoV-2 assay kit (Oxford Immunotec, UK) and the Abbott SARS-CoV-2 IgG II quantification assay (Abbott SARS-CoV-2 IgG II Quant assay; Abbott, Lake Bluff, IL, USA)
Questionnaire: The survey asked the following questions; age, sex, underlying medical conditions, medications, adverse reactions to COVID-19 vaccination, history of COVID-19 infection, and symptoms during infection in those with a history of COVID-19


Management information

Registered date

2022 Year 12 Month 19 Day

Last modified on

2022 Year 12 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056765


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name